Benefit studies and safety surveillance answer different questions
- Evidence
- 2017 review: 33 trials, 7,175 participants
- What it can tell us
- Possible cough and sore-throat symptom improvements, with poor overall study quality and varied productsSee reference 1
- Evidence
- Australian safety review and 2025 data update
- What it can tell us
- Reports of serious allergy, including after earlier uneventful use; short efficacy trials cannot exclude this riskSee reference 2
- Evidence
- New Zealand safety reminder
- What it can tell us
- Similar concern outside Australia; consumers and clinicians need the actual ingredient listSee reference 4
Symptom relief is narrower than an immune-boosting claim
The 2017 review combined different preparations, mixtures and comparison treatments. Manufacturing and quality details were often missing. Its findings do not establish that every product prevents colds, treats severe infection or improves immunity in a healthy person. The authors called for better trials.See reference 1
The review excluded pregnancy and breastfeeding and could not fully resolve children-specific or lower-respiratory-infection effects. It does not supply a generally safe dose for those groups. This page does not choose a dose, recommend a product or advise replacing prescribed care.See reference 1
A 2018 correction disclosed that one author’s doctoral stipend was supported by Pukka Herbs. This adds relevant funding context to the uncertain review findings.See reference 5
The important safety finding is unpredictable serious allergy
The TGA’s April 2026 summary reports 287 anaphylaxis reports associated with andrographis-containing medicines through 31 December 2025, including one fatal case reported in 2024. Reports are safety signals, not a denominator-based estimate of an individual’s chance of a reaction.See reference 2
The TGA says reactions can happen on first use or after previous use without problems. Its summary also notes that many affected people had no history of allergy or asthma. “I have taken it before” and “I do not have allergies” therefore do not clear the risk.See reference 2
What changed in Australia in September 2026
From 17 September 2026, andrographis was removed from the Australian list of ingredients permitted in new low-risk listed medicines. The TGA concluded that the severe-allergy risk was not adequately manageable within that framework.See reference 3
That decision did not instantly remove every existing product from shelves, and it is not a statement about the law in every country. Actions on existing products can be product-specific. Check the regulator’s current recall information and follow the instructions for the actual product you have.See reference 3
A suspected reaction needs attention, not a home retest
Medsafe advises stopping an andrographis-containing product after an allergic reaction and avoiding future products containing it. Mixtures can make the trigger less obvious, so keep the full label available for the assessing clinician. Do not try another dose to see whether the reaction happens again.See reference 4
Anaphylaxis is an emergency. If a severe reaction is suspected, call for emergency medical help immediately. Breathing difficulty, throat swelling or collapse after a product can be warning signs; this page cannot assess the cause or severity remotely.See reference 2,See reference 4
A label needs more detail than “herbal immune support”
Medsafe notes that andrographis is often mixed with other ingredients. Check for Andrographis paniculata in the full list and preserve the product name and batch details when reporting a suspected problem. A different brand or an added herb does not demonstrate that a previous reaction has been avoided.See reference 4
Keep the useful details
- Keep uncertain symptom evidence separate from a safety guarantee.See reference 1,See reference 2
- Earlier uneventful use does not rule out a later serious reaction.See reference 2
- Regulatory and recall instructions depend on the jurisdiction and exact product.See reference 3
Common questions
Does a trial with no serious adverse event prove the product is safe?
No. Short efficacy studies and real-world safety reports have different limits. The regulator’s serious-allergy evidence remains relevant.See reference 1,See reference 2
Was every andrographis product immediately banned worldwide?
No. The September 2026 decision concerns eligibility for new Australian listed medicines. Existing-product actions and other countries’ rules need separate checks.See reference 3
Can I safely restart because I used it without problems before?
Previous tolerance does not establish safety. The TGA describes serious reactions after earlier uneventful use.See reference 2
Get the weekly longevity brief
The week's best longevity research in plain English. Free, every Tuesday.
References
- 1. Andrographis paniculata for symptomatic relief of acute respiratory tract infections: systematic review and meta-analysis
Hu and colleagues, PLOS ONE; 2017Systematic review
- 2. Andrographis and anaphylaxis: updated safety review and supplementary report
Australian Therapeutic Goods Administration; April 2026Official guidance
- 3. High-moderate risk changes to permissible ingredients: Andrographis paniculata 2026
Australian Therapeutic Goods Administration; September 2026Official guidance
- 4. Reminder: allergic reactions with Andrographis paniculata
New Zealand Medsafe, Prescriber Update; December 2025Official guidance
- 5. Correction: andrographis respiratory-infection systematic review
Hu and colleagues, PLOS ONE; November 2018Systematic review
Editorial transparency
- Published by
- LongevityMate Editorial
- Review
- Editorial evidence review (AI-assisted)
- Published
- Updated
Medical disclaimer
General education only. AI-assisted editorial evidence review is not a qualified clinical assessment. This guide does not diagnose a condition, interpret a personal result, choose treatment or recommend a supplement dose. Discuss testing, symptoms, medicines and supplements with a qualified health professional.
